Searching. Please wait…
1582
37
171
29406
4423
2606
347
392
Abstract: Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ?5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
Fuente: Blood Cancer Journal, 2021, 11(12), 192
Publisher: Nature Pub. Group
Year of publication: 2021
No. of pages: 5
Publication type: Article
DOI: 10.1038/s41408-021-00587-0
ISSN: 2044-5385
Publication Url: https://www.doi.org/10.1038/s41408-021-00587-0
Google Scholar
Citations
UCrea Repository Read publication
FERNÁNDEZ DE LARREA, CARLOS
KYLE, ROBERT
ROSIÑOL, LAURA
PAIVA, BRUNO
ENGELHARDT, MONIKA
USMANI, SAAD
CAERS, JO
GONSALVES, WILSON
SCHJESVOLD, FREDRIK
MERLINI, GIAMPAOLO
LENTZCH, SUZANNE
ENRIQUE MARIA OCIO SAN MIGUEL
GARDERET, LAURENT
MOREAU, PHILIPPE
SONNEVELD, PIETER
BADROS, ASHRAF
GAHRTON, GÖSTA
GOLDSCHMIDT, HARTMUT
TUCHMAN, SASCHA
EINSELE, HERMANN
Back